CORVEL CORP (CRVL) Stock Fundamental Analysis
NASDAQ:CRVL - US2210061097 - Common Stock
85.48 USD
-0.49 (-0.57%)
85.48 USD
0 (0%)
Overall CRVL gets a fundamental rating of 6 out of 10. We evaluated CRVL against 101 industry peers in the Health Care Providers & Services industry. CRVL gets an excellent profitability rating and is at the same time showing great financial health properties. CRVL is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CRVL was profitable.
CRVL had a positive operating cash flow in the past year.
In the past 5 years CRVL has always been profitable.
CRVL had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
CRVL has a better Return On Assets (16.88%) than 99.01% of its industry peers.
CRVL has a Return On Equity of 29.43%. This is amongst the best in the industry. CRVL outperforms 94.06% of its industry peers.
The Return On Invested Capital of CRVL (28.10%) is better than 98.02% of its industry peers.
CRVL had an Average Return On Invested Capital over the past 3 years of 28.60%. This is significantly above the industry average of 9.19%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.88% | ||
| ROE | 29.43% | ||
| ROIC | 28.1% |
ROA(3y)17.02%
ROA(5y)15.59%
ROE(3y)31.06%
ROE(5y)29.09%
ROIC(3y)28.6%
ROIC(5y)26.25%
1.3 Margins
The Profit Margin of CRVL (10.98%) is better than 95.05% of its industry peers.
In the last couple of years the Profit Margin of CRVL has grown nicely.
With an excellent Operating Margin value of 13.94%, CRVL belongs to the best of the industry, outperforming 84.16% of the companies in the same industry.
CRVL's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 23.79%, CRVL is in line with its industry, outperforming 49.51% of the companies in the same industry.
In the last couple of years the Gross Margin of CRVL has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.94% | ||
| PM (TTM) | 10.98% | ||
| GM | 23.79% |
OM growth 3Y1.04%
OM growth 5Y5.65%
PM growth 3Y1.12%
PM growth 5Y5.84%
GM growth 3Y-0.17%
GM growth 5Y1.95%
2. Health
2.1 Basic Checks
CRVL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, CRVL has about the same amount of shares outstanding.
Compared to 5 years ago, CRVL has less shares outstanding
There is no outstanding debt for CRVL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
CRVL has an Altman-Z score of 15.12. This indicates that CRVL is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 15.12, CRVL belongs to the best of the industry, outperforming 97.03% of the companies in the same industry.
There is no outstanding debt for CRVL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 15.12 |
ROIC/WACC3.21
WACC8.74%
2.3 Liquidity
A Current Ratio of 1.79 indicates that CRVL should not have too much problems paying its short term obligations.
CRVL has a better Current ratio (1.79) than 64.36% of its industry peers.
A Quick Ratio of 1.79 indicates that CRVL should not have too much problems paying its short term obligations.
The Quick ratio of CRVL (1.79) is better than 65.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.79 | ||
| Quick Ratio | 1.79 |
3. Growth
3.1 Past
CRVL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.39%, which is quite impressive.
CRVL shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 16.86% yearly.
The Revenue has grown by 12.46% in the past year. This is quite good.
CRVL shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.62% yearly.
EPS 1Y (TTM)30.39%
EPS 3Y14.48%
EPS 5Y16.86%
EPS Q2Q%27.95%
Revenue 1Y (TTM)12.46%
Revenue growth 3Y11.49%
Revenue growth 5Y8.62%
Sales Q2Q%10.86%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 44.29, which means the current valuation is very expensive for CRVL.
CRVL's Price/Earnings ratio is in line with the industry average.
CRVL's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.06.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 44.29 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CRVL is on the same level as its industry peers.
The rest of the industry has a similar Price/Free Cash Flow ratio as CRVL.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 44.6 | ||
| EV/EBITDA | 26.4 |
4.3 Compensation for Growth
CRVL has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)2.63
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for CRVL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
85.48
-0.49 (-0.57%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners53.88%
Inst Owner Change-2.17%
Ins Owners7.11%
Ins Owner Change-0.31%
Market Cap4.39B
Analysts0
Price TargetN/A
Short Float %2.38%
Short Ratio4.27
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 44.29 | ||
| Fwd PE | N/A | ||
| P/S | 4.77 | ||
| P/FCF | 44.6 | ||
| P/OCF | 30.91 | ||
| P/B | 12.8 | ||
| P/tB | 14.37 | ||
| EV/EBITDA | 26.4 |
EPS(TTM)1.93
EY2.26%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)1.92
FCFY2.24%
OCF(TTM)2.77
OCFY3.24%
SpS17.9
BVpS6.68
TBVpS5.95
PEG (NY)N/A
PEG (5Y)2.63
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.88% | ||
| ROE | 29.43% | ||
| ROCE | 35.36% | ||
| ROIC | 28.1% | ||
| ROICexc | 63.53% | ||
| ROICexgc | 82.75% | ||
| OM | 13.94% | ||
| PM (TTM) | 10.98% | ||
| GM | 23.79% | ||
| FCFM | 10.71% |
ROA(3y)17.02%
ROA(5y)15.59%
ROE(3y)31.06%
ROE(5y)29.09%
ROIC(3y)28.6%
ROIC(5y)26.25%
ROICexc(3y)48.46%
ROICexc(5y)45.93%
ROICexgc(3y)62.9%
ROICexgc(5y)61.44%
ROCE(3y)35.98%
ROCE(5y)33.03%
ROICexcg growth 3Y4.75%
ROICexcg growth 5Y18.9%
ROICexc growth 3Y6.87%
ROICexc growth 5Y18.29%
OM growth 3Y1.04%
OM growth 5Y5.65%
PM growth 3Y1.12%
PM growth 5Y5.84%
GM growth 3Y-0.17%
GM growth 5Y1.95%
F-Score8
Asset Turnover1.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 143.25% | ||
| Cap/Sales | 4.74% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 89.54% | ||
| Profit Quality | 97.54% | ||
| Current Ratio | 1.79 | ||
| Quick Ratio | 1.79 | ||
| Altman-Z | 15.12 |
F-Score8
WACC8.74%
ROIC/WACC3.21
Cap/Depr(3y)112.41%
Cap/Depr(5y)107.09%
Cap/Sales(3y)3.78%
Cap/Sales(5y)3.81%
Profit Quality(3y)90.78%
Profit Quality(5y)99.01%
High Growth Momentum
Growth
EPS 1Y (TTM)30.39%
EPS 3Y14.48%
EPS 5Y16.86%
EPS Q2Q%27.95%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)12.46%
Revenue growth 3Y11.49%
Revenue growth 5Y8.62%
Sales Q2Q%10.86%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y31.08%
EBIT growth 3Y12.65%
EBIT growth 5Y14.76%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y49.21%
FCF growth 3Y34.78%
FCF growth 5Y13.57%
OCF growth 1Y59.6%
OCF growth 3Y23.73%
OCF growth 5Y9.51%